Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668772 · ClinicalTrials.gov registry record · Phase 3
Tiotropium/Salmeterol Inhalation Powder in COPD
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 3
- Development phase
- 207
- Enrollment target
NCT00668772 is a Phase 3 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 207 participants.
The verdict
NCT00668772, a Phase 3 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 207 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the SGRQ and the effect on COPD exacerbations
Interventions
- DRUG Placebo
- DRUG Tiotropium
- DRUG Salmeterol
- DRUG Tiotropium/Salmeterol
- DRUG Tiotropium/Salmeterol QD + Salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2008-04-15 |
| Est. Completion | 2008-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668772
The ClinicalTrials.gov registry entry for NCT00668772 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 207 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00668772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668772 about?
NCT00668772 is a clinical study titled "Tiotropium/Salmeterol Inhalation Powder in COPD". The primary objectives of this study are to assess bronchodilator efficacy as determined by FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as determined bt the SGRQ and the effect on COPD exacerbations
What is the current status of trial NCT00668772?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 207 participants. The study started on 2008-04-15. Estimated completion is 2008-11-21.
What interventions are being tested in trial NCT00668772?
The interventions under investigation include: Placebo (DRUG), Tiotropium (DRUG), Salmeterol (DRUG), Tiotropium/Salmeterol (DRUG), Tiotropium/Salmeterol QD + Salmeterol (DRUG).
Who is sponsoring clinical trial NCT00668772?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.